한글목차

세계의 심바스타틴 시장은 2024년에 1억 4,693만 달러로 평가되었고, 예측 기간 동안 CAGR 6.51%로 성장할 전망이며, 2030년에는 2억 2,687만 달러에 이를 것으로 예측되고 있습니다.

심바스타틴은 스타틴 클래스에 속하는 콜레스테롤 저하제로 고콜레스테롤 혈증의 관리 및 심혈관 합병증의 예방에 널리 사용되고 있습니다. 예방 의료와 콜레스테롤 관리에 대한 사회적 관심의 고조가 성숙 시장과 신흥 시장 모두에서 수요를 촉진하고 있습니다. 이 시장은 비만, 당뇨병, 고혈압 등의 라이프스타일과 관련된 질환의 유병률 상승으로부터 이익을 얻고 있으며, 이러한 질환은 심혈관 위험을 높이고 조기에 스타틴 치료를 촉진하고 있습니다. 심바스타틴은 이용 가능한 치료법 중에서도 확립된 비용 대비 효과가 높은 선택지입니다. 저소득 국가에서는 헬스케어 서비스에 대한 접근성이 확대되고 제네릭 의약품 가격도 저렴해진 것이 시장 확대를 뒷받침하고 있습니다. 그러나 업계는 대체 지질 저하 요법과의 경합, 스타틴의 장기 사용에 관한 안전성에 관한 우려, 제조업체의 가격 설정이나 이익률에 영향을 주는 규제상의 제약 등과도 싸우고 있습니다.

시장 성장 촉진요인

제약 산업의 성장

주요 시장 과제

안전에 대한 우려 및 부작용

주요 시장 동향

정부의 건강 관리 지출 증가

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 COVID-19가 세계의 심바스타틴 시장에 미치는 영향

제5장 세계의 심바스타틴 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율 및 예측
  • 판매 채널별(직접, 간접)
  • 용도별(고지혈증, 관동맥성 심질환, 당뇨병성 지질이상증, 뇌졸중, 기타)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 북미의 심바스타틴 시장 전망

• 시장 규모 및 예측
• 시장 점유율 및 예측
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제7장 유럽의 심바스타틴 시장 전망

• 시장 규모 및 예측
• 시장 점유율 및 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 심바스타틴 시장 전망

• 시장 규모 및 예측
• 시장 점유율 및 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 한국
  • 일본
  • 호주

제9장 남미의 심바스타틴 시장 전망

• 시장 규모 및 예측
• 시장 점유율 및 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 심바스타틴 시장 전망

• 시장 규모 및 예측
• 시장 점유율 및 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향 및 발전

• 합병 및 인수
• 제품 출시
• 최근 동향

제13장 세계의 심바스타틴 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

• 업계 내 경쟁
• 신규 진입의 가능성
• 공급자의 힘
• 고객의 힘
• 대체품의 위협

제15장 경쟁 구도

• ASolution Pharmaceuticals Pvt. Ltd
• Cipla Ltd
• Cadila Healthcare Limited
• Jsons Laboratories
• SHIVA LIFE SCIENCE PVT LTD
• Kaizen Pharmachem
• Rajem Pharmascience Pvt Ltd
• Jubilant Generics Limited
• Chemneal Pharmaceuticals LLP
• Sun Pharmaceutical Industries Limited

제16장 전략적 제안

제17장 기업 소개 및 면책사항

영문목차

The Global Simvastatin Market was valued at USD 146.93 million in 2024 and is projected to reach USD 226.87 million by 2030, growing at a CAGR of 6.51% during the forecast period. Simvastatin, a cholesterol-lowering drug in the statin class, is extensively used for managing hypercholesterolemia and preventing cardiovascular complications. Increasing public focus on preventive healthcare and cholesterol control is fueling its demand across both mature and emerging markets. The market benefits from the rising prevalence of lifestyle-related disorders such as obesity, diabetes, and hypertension-conditions that heighten cardiovascular risks and prompt early statin therapy. Simvastatin remains a well-established and cost-effective option among available treatments. Broader access to healthcare services and greater affordability of generic drugs in lower-income nations are supporting market expansion. However, the industry also contends with competition from alternative lipid-lowering therapies, safety-related concerns regarding long-term statin use, and regulatory constraints that may impact pricing and profit margins for manufacturers.

Key Market Drivers

Growth in Pharmaceutical Industry

The expansion of the global pharmaceutical industry is a major driver propelling simvastatin demand. With the pharmaceutical sector generating over USD 1.6 trillion in revenue by 2023, its scale is now comparable to the GDP of entire nations. This growth reflects a heightened industry focus on chronic disease management, including cardiovascular conditions-a key area where statins like simvastatin play a central role. As companies increase investments in accessible, cost-effective therapies, the use of generic statins continues to rise globally. Simvastatin, due to its proven efficacy and affordability, remains a staple treatment, particularly in managing long-term cardiovascular risk in both primary and secondary prevention cases.

Key Market Challenges

Safety Concerns and Side Effects

Safety concerns related to simvastatin pose a significant challenge to its continued uptake. Although effective in managing cholesterol levels and lowering cardiovascular risk, simvastatin has been associated with muscle-related side effects, ranging from mild discomfort to serious conditions such as myopathy and rhabdomyolysis. These risks, especially with prolonged use or when combined with interacting drugs like antifungals or immunosuppressants, have led to increased caution among healthcare providers and patients. Regulatory bodies continue to evaluate the risk-benefit profile of simvastatin, and some patients may avoid or discontinue therapy due to perceived or actual adverse effects. These safety issues can impact treatment adherence and overall market performance.

Key Market Trends

Increasing Government Healthcare Spending

Rising government expenditure on healthcare is a key trend supporting simvastatin market growth. In 2023, the U.S. reported healthcare spending of USD 13,432 per capita-well above the average of USD 7,393 among other high-income countries. Similar trends are emerging globally as nations prioritize public health infrastructure and chronic disease prevention. Simvastatin, frequently included on essential medicine lists, benefits from government-led programs that subsidize or reimburse treatments for hyperlipidemia and cardiovascular disease. By supporting early intervention and preventative care through expanded access to medicines, increased public spending plays a crucial role in boosting simvastatin usage, particularly in regions implementing large-scale cardiovascular disease mitigation strategies.

Key Market Players

• ASolution Pharmaceuticals Pvt. Ltd
• Cipla Ltd
• Cadila Healthcare Limited
• Jsons Laboratories
• SHIVA LIFE SCIENCE PVT LTD
• Kaizen Pharmachem
• Rajem Pharmascience Pvt Ltd
• Jubilant Generics Limited
• Chemneal Pharmaceuticals LLP
• Sun Pharmaceutical Industries Limited

Report Scope:

In this report, the Global Simvastatin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Simvastatin Market, By Sales Channel:

• Direct
• Indirect

Simvastatin Market, By End Use:

• Hyperlipidemia
• Coronary Heart Disease
• Diabetes-Related Dyslipidemia
• Stroke
• Others

Simvastatin Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Simvastatin Market.

Available Customizations:

Global Simvastatin Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Simvastatin Market

5. Global Simvastatin Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Sales Channel (Direct, Indirect)
  • 5.2.2. By End Use (Hyperlipidemia, Coronary Heart Disease, Diabetes-Related Dyslipidemia, Stroke, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Simvastatin Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Sales Channel
  • 6.2.2. By End Use
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Simvastatin Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Sales Channel
      • 6.3.1.2.2. By End Use
  • 6.3.2. Mexico Simvastatin Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Sales Channel
      • 6.3.2.2.2. By End Use
  • 6.3.3. Canada Simvastatin Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Sales Channel
      • 6.3.3.2.2. By End Use

7. Europe Simvastatin Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Sales Channel
  • 7.2.2. By End Use
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Simvastatin Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Sales Channel
      • 7.3.1.2.2. By End Use
  • 7.3.2. Germany Simvastatin Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Sales Channel
      • 7.3.2.2.2. By End Use
  • 7.3.3. United Kingdom Simvastatin Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Sales Channel
      • 7.3.3.2.2. By End Use
  • 7.3.4. Italy Simvastatin Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Sales Channel
      • 7.3.4.2.2. By End Use
  • 7.3.5. Spain Simvastatin Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Sales Channel
      • 7.3.5.2.2. By End Use

8. Asia Pacific Simvastatin Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Sales Channel
  • 8.2.2. By End Use
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Simvastatin Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Sales Channel
      • 8.3.1.2.2. By End Use
  • 8.3.2. India Simvastatin Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Sales Channel
      • 8.3.2.2.2. By End Use
  • 8.3.3. South Korea Simvastatin Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Sales Channel
      • 8.3.3.2.2. By End Use
  • 8.3.4. Japan Simvastatin Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Sales Channel
      • 8.3.4.2.2. By End Use
  • 8.3.5. Australia Simvastatin Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Sales Channel
      • 8.3.5.2.2. By End Use

9. South America Simvastatin Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Sales Channel
  • 9.2.2. By End Use
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Simvastatin Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Sales Channel
      • 9.3.1.2.2. By End Use
  • 9.3.2. Argentina Simvastatin Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Sales Channel
      • 9.3.2.2.2. By End Use
  • 9.3.3. Colombia Simvastatin Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Sales Channel
      • 9.3.3.2.2. By End Use

10. Middle East and Africa Simvastatin Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Sales Channel
  • 10.2.2. By End Use
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Simvastatin Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Sales Channel
      • 10.3.1.2.2. By End Use
  • 10.3.2. Saudi Arabia Simvastatin Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Sales Channel
      • 10.3.2.2.2. By End Use
  • 10.3.3. UAE Simvastatin Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Sales Channel
      • 10.3.3.2.2. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Simvastatin Market: SWOT Analysis

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. ASolution Pharmaceuticals Pvt. Ltd
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Cipla Ltd
• 15.3. Cadila Healthcare Limited
• 15.4. Jsons Laboratories
• 15.5. SHIVA LIFE SCIENCE PVT LTD
• 15.6. Kaizen Pharmachem
• 15.7. Rajem Pharmascience Pvt Ltd
• 15.8. Jubilant Generics Limited
• 15.9. Chemneal Pharmaceuticals LLP
• 15.10. Sun Pharmaceutical Industries Limited

16. Strategic Recommendations

17. About Us & Disclaimer